Table 2. Participants' characteristics at baseline by exposure status at the end of the follow-up period, age cohort 60–79 years, COVID-19 vaccine effectiveness study, Portugal, 15 May–31 July 2022 (n = 1,984,107).
| Unvaccinated (n = 147,512) | Primary series (n = 220,699) | First booster (n = 1,615,896) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||||
| Age in years, median (IQR) | 68.0 (63.0–73.0) | 67.0 (63.0–72.0) | 69.0 (65.0 – 74.0) | ||||||
| Age group | |||||||||
| 60–64 | 49,832 | 33.8 | 78,648 | 35.6 | 402,090 | 24.9 | |||
| 65–69 | 37,828 | 25.6 | 58,750 | 26.6 | 451,544 | 27.9 | |||
| 70–74 | 33,054 | 22.4 | 47,360 | 21.5 | 438,185 | 27.1 | |||
| 75–79 | 26,798 | 18.2 | 35,941 | 16.3 | 324,077 | 20.1 | |||
| Male sex | 69,802 | 47.3 | 98,113 | 44.5 | 733,273 | 45.4 | |||
| Region | |||||||||
| ARS Alentejo | 5,626 | 3.8 | 8,917 | 4.0 | 78,900 | 4.9 | |||
| ARS Algarve | 15,324 | 10.4 | 13,240 | 6.0 | 75,145 | 4.7 | |||
| ARS Centro | 22,902 | 15.5 | 35,640 | 16.1 | 288,851 | 17.9 | |||
| ARS LVT | 52,152 | 35.4 | 76,948 | 34.9 | 556,184 | 34.4 | |||
| ARS Norte | 32,406 | 22.0 | 83,339 | 37.8 | 608,265 | 37.6 | |||
| Missing | 19,102 | 12.9 | 2,615 | 1.2 | 8,551 | 0.5 | |||
| European deprivation index quintile | |||||||||
| Q1 (least deprived) | 16,777 | 11.4 | 28,032 | 12.7 | 238,864 | 14.8 | |||
| Q2 | 17,048 | 11.6 | 30,038 | 13.6 | 241,030 | 14.9 | |||
| Q3 | 16,564 | 11.2 | 31,766 | 14.4 | 238,676 | 14.8 | |||
| Q4 | 34,792 | 23.6 | 62,347 | 28.2 | 464,215 | 28.7 | |||
| Q5 (most deprived) | 43,229 | 29.3 | 65,901 | 29.9 | 424,560 | 26.3 | |||
| Missing | 19,102 | 12.9 | 2,615 | 1.2 | 8,551 | 0.5 | |||
| Number of chronic diseases | |||||||||
| 0 | 81,499 | 55.2 | 65,604 | 29.7 | 421,596 | 26.1 | |||
| 1 | 31,436 | 21.3 | 55,312 | 25.1 | 420,812 | 26.0 | |||
| 2 | 19,093 | 12.9 | 47,571 | 21.6 | 378,138 | 23.4 | |||
| 3 | 9,613 | 6.5 | 30,688 | 13.9 | 239,821 | 14.8 | |||
| 4 | 4,034 | 2.7 | 14,192 | 6.4 | 105,536 | 6.5 | |||
| ≥ 5 | 1,837 | 1.2 | 7,332 | 3.3 | 49,993 | 3.1 | |||
| Number of SARS-CoV-2 tests | |||||||||
| 0 | 86,350 | 58.5 | 49,951 | 22.6 | 601,190 | 37.2 | |||
| 1 | 26,439 | 17.9 | 50,811 | 23.0 | 360,039 | 22.3 | |||
| 2 | 13,366 | 9.1 | 36,574 | 16.6 | 233,889 | 14.5 | |||
| 3 | 7,244 | 4.9 | 24,951 | 11.3 | 144,098 | 8.9 | |||
| 4–9 | 11,813 | 8.0 | 49,497 | 22.4 | 244,315 | 15.1 | |||
| ≥ 10 | 2,300 | 1.6 | 8,915 | 4.0 | 32,365 | 2.0 | |||
| Any other vaccine uptakea | 15,161 | 10.3 | 103,616 | 46.9 | 1,143,377 | 70.8 | |||
ARS: regional health administration; COVID-19: coronavirus disease; LVT: Lisbon and Tagus Valley; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
a Received at least one of the following vaccines since 2016, influenza vaccine, pneumococcal conjugate vaccines (PCV13, PCV7, or PCV10) and pneumococcal polysaccharide vaccine (PPSV23).